FibroGen’s (FGEN) Market Perform Rating Reaffirmed at William Blair

FibroGen (NASDAQ:FGEN)‘s stock had its “market perform” rating restated by research analysts at William Blair in a report released on Wednesday,RTT News reports.

Separately, StockNews.com initiated coverage on FibroGen in a research report on Wednesday, November 6th. They issued a “hold” rating on the stock.

FibroGen Trading Up 14.2 %

FGEN opened at $0.39 on Wednesday. The stock has a market cap of $38.82 million, a PE ratio of -0.23 and a beta of 0.72. FibroGen has a 1 year low of $0.29 and a 1 year high of $2.93. The stock’s 50 day simple moving average is $0.37 and its 200-day simple moving average is $0.73.

Institutional Trading of FibroGen

A number of large investors have recently bought and sold shares of the stock. Alpine Global Management LLC bought a new stake in FibroGen in the first quarter valued at $25,000. Delap Wealth Advisory LLC bought a new position in FibroGen in the first quarter valued at about $27,000. Acadian Asset Management LLC boosted its holdings in FibroGen by 1.4% in the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock valued at $5,883,000 after acquiring an additional 34,937 shares during the last quarter. Sei Investments Co. boosted its holdings in FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 41,442 shares during the last quarter. Finally, Point72 DIFC Ltd boosted its holdings in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the last quarter. 72.71% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.